AUTHOR OF THIS BLOG

DR ANTHONY MELVIN CRASTO, WORLDDRUGTRACKER
Apr 302014
 

Europe green light for GSK COPD drug

Regulators in Europe have given the green light to GlaxoSmithKline’s new chronic obstructive pulmonary disease drug Incruse.

Specifically, the European Commission has granted marketing authorisation for Incruse (umeclidinium) as a once-daily treatment to relieve symptoms in adults with COPD. The drug is a once-daily long-acting muscarinic antagonist (LAMA) delivered by GSK’s Ellipta inhaler.

Read more at: http://www.pharmatimes.com/Article/14-04-28/Europe_green_light_for_GSK_COPD_drug.aspx#ixzz30Lohff26
Follow us: @PharmaTimes on Twitter

read

http://www.pharmatimes.com/Article/14-04-28/Europe_green_light_for_GSK_COPD_drug.aspx

Share

Sorry, the comment form is closed at this time.

Follow

Get every new post on this blog delivered to your Inbox.

Join other followers: